3-<3.4.5-Trimethoxyphenyl>-pyrazolin-5-on | 1575-01-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-<3.4.5-Trimethoxyphenyl>-pyrazolin-5-on
• 英文别名: 5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrazol-3-one；5-(3,4,5-Trimethoxyphenyl)-2,4-Dihydro-Pyrazol-3-one；3-(3,4,5-trimethoxyphenyl)-1,4-dihydropyrazol-5-one
• CAS: 1575-01-5
• 化学式: C₁₂H₁₄N₂O₄
• 分子量: 250.254
• InChiKey: XCRVBPZLDVOGLN-UHFFFAOYSA-N

物化性质

• 熔点：
  233 °C
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  69.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  甲氧苯胺 、 3-<3.4.5-Trimethoxyphenyl>-pyrazolin-5-on 在 盐酸 、 sodium nitrite 、 potassium acetate 作用下， 以 水 、 乙醇 为溶剂， 反应 1.0h， 生成 4-[2-(4-methoxyphenyl)hydrazinyl]-5-(3,4,5-trimethoxyphenyl)pyrazol-3-one
  参考文献：
  名称：

  3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3β

  摘要：

  A series of 3-aryl-4-(arylhydrazono)-1H-pyrazol-5-one inhibitors of GSK3 beta was developed from a low molecular weight, highly ligand efficient screening hit 1. Hit-to-lead optimization led to a number of highly potent inhibitors, while maintaining the high ligand efficiency of the screening hit. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.072
• 作为产物：
  描述：

  3-氧代-3-(3,4,5-三甲氧基苯基)丙酸甲酯 在 肼 作用下， 以 乙醇 为溶剂， 生成 3-<3.4.5-Trimethoxyphenyl>-pyrazolin-5-on
  参考文献：
  名称：

  3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3β

  摘要：

  A series of 3-aryl-4-(arylhydrazono)-1H-pyrazol-5-one inhibitors of GSK3 beta was developed from a low molecular weight, highly ligand efficient screening hit 1. Hit-to-lead optimization led to a number of highly potent inhibitors, while maintaining the high ligand efficiency of the screening hit. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.072

文献信息

• Inhibitors of GSK-3 and uses thereof
  申请人：——

  公开号：US20040024040A1

  公开（公告）日：2004-02-05

  The present invention relates to compounds of formula I that are useful as GSK-3 inhibitors. The invention also relates to methods of using compounds of formula I or pharmaceutical compositions comprising compounds of formula I to inhibit GSK-3 activity. The invention further provides methods of utilizing these compounds and pharmaceutical compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. The invention also relates to methods for inhibiting Aurora-2 activity and for treating or preventing Aurora-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I. The invention also relates to methods for inhibiting cyclin-dependent kinase-2 activity and for treating or preventing inhibiting cyclin-dependent kinase-2-mediated diseases using compounds of formula I or pharmaceutical compositions comprising compounds of formula I.

  本发明涉及公式I的化合物，其作为GSK-3抑制剂有用。本发明还涉及使用公式I的化合物或包含公式I的制药组合物来抑制GSK-3活性的方法。本发明进一步提供了利用这些化合物和制药组合物在治疗和预防各种疾病，如糖尿病和阿尔茨海默病中的方法。本发明还涉及使用公式I的化合物或包含公式I的制药组合物抑制Aurora-2活性和治疗或预防Aurora-2介导的疾病的方法。本发明还涉及使用公式I的化合物或包含公式I的制药组合物抑制细胞周期素依赖性激酶-2活性和治疗或预防细胞周期素依赖性激酶-2介导的疾病的方法。
• US6916798B2
  申请人：——

  公开号：US6916798B2

  公开（公告）日：2005-07-12
• US7452873B2
  申请人：——

  公开号：US7452873B2

  公开（公告）日：2008-11-18
• [EN] PYRAZOLON DERIVATIVES AS INHIBITORS OF GSK-3<br/>[FR] DERIVES DE PYRAZOLE COMME INHIBITEURS DE GSK-3
  申请人：VERTEX PHARMA

  公开号：WO2003011287A1

  公开（公告）日：2003-02-13

  The present invention relates to compounds of formula (I) that are useful as GSK-3 inhibitors. The invention also relates to methods of using compounds of formula (I) or pharmaceutical compositions comprising compounds of formula (I) to inhibit GSK-3 activity. The invention further provides methods of utilizing these compounds and pharmaceutical compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. The invention also relates to methods for inhibiting Aurora-2 activity and for treating or preventing Aurora-2-mediated diseases using compounds of formula (I) or pharmaceutical compositions comprising compounds of formula (I). The invention also relates to methods for inhibiting cyclin-dependent kinase-2 activity and for treating or preventing inhibiting cyclin-dependent kinase-2-mediated diseases using compounds of formula (I) or pharmaceutical compositions comprising compounds of formula (I).
• 3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3β
  作者：Michael Arnost、Al Pierce、Ernst ter Haar、David Lauffer、Jaren Madden、Kirk Tanner、Jeremy Green

  DOI：10.1016/j.bmcl.2010.01.072

  日期：2010.3

  A series of 3-aryl-4-(arylhydrazono)-1H-pyrazol-5-one inhibitors of GSK3 beta was developed from a low molecular weight, highly ligand efficient screening hit 1. Hit-to-lead optimization led to a number of highly potent inhibitors, while maintaining the high ligand efficiency of the screening hit. (C) 2010 Elsevier Ltd. All rights reserved.